BusinessCytokinetics, Inc. Reports Third Quarter 2017 Financial ResultsBy Nasdaq OMXOct 26, 2017, 8:00 PM UTC
BusinessCytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart FailureBy Nasdaq OMXSep 19, 2017, 11:30 AM UTC
BusinessCytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific MeetingBy Nasdaq OMXSep 18, 2017, 11:30 AM UTC
BusinessCytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific MeetingBy Nasdaq OMXSep 11, 2017, 8:00 PM UTC
BusinessCytokinetics to Present at September Investor ConferencesBy Nasdaq OMXSep 5, 2017, 8:00 PM UTC
BusinessCytokinetics, Inc. Reports Second Quarter 2017 Financial ResultsBy Nasdaq OMXAug 2, 2017, 8:00 PM UTC
BusinessCytokinetics Announces Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients With Heart FailureBy Nasdaq OMXAug 2, 2017, 11:30 AM UTC
BusinessCytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral SclerosisBy Nasdaq OMXJul 27, 2017, 11:30 AM UTC
